This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thompson, E. J. Articles by Gendler, S. J. Search for Related Content PubMed PubMed Citation Articles by Thompson, E. J. Articles by Gendler, S. J.

---

Signaling and Regulation

Tyrosines in the MUC1 Cytoplasmic Tail Modulate Transcription via the Extracellular Signal-Regulated Kinase 1/2 and Nuclear Factor-B Pathways

¹ Cancer Center Scottsdale and ² Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona

Requests for reprints: Sandra J. Gendler, Mayo Clinic Arizona, Johnson Research Building, 13400 East Shea Boulevard, Scottsdale, AZ 85259. Phone: 480-301-7062; Fax: 480-301-7017. E-mail: gendler.sandra{at}mayo.edu

Much of the ability of the MUC1 oncoprotein to foster tumorigenesis and tumor progression likely originates from the interaction of its cytoplasmic tail with proteins involved in oncogenic signaling. Many of these interactions are regulated by phosphorylation, as the cytoplasmic tail contains seven highly conserved tyrosines and several serine/threonine phosphorylation sites. We have developed a cell line–based model system to study the effects of tyrosine phosphorylation on MUC1 signaling, with particular emphasis on its effects on gene transcription. COS-7 cells, which lack endogenous MUC1, were stably infected with wild-type MUC1 or a MUC1 construct lacking all seven tyrosines (MUC1 Y0) and analyzed for effects on transcription mediated by the extracellular signal-regulated kinase 1/2 (ERK1/2) and nuclear factor-B (NF-B) pathways. COS.MUC1 Y0 cells showed heightened active ERK1/2 with increased activator protein-1 (AP-1) and signal transducer and activator of transcription 3 (STAT3) transcriptional activity; there was also a simultaneous decrease in NF-B transcriptional activity and nuclear localization. These changes altered the phenotype of COS.MUC1 Y0 cells, as this line displayed increased invasion and enhanced [³H]thymidine incorporation. Analysis of the three lines also showed significant differences in their cell cycle profile and bromodeoxyuridine incorporation when the cells were serum starved. These data support the growing evidence that MUC1 is involved in transcriptional regulation and link MUC1 for the first time to the NF-B pathway. (Mol Cancer Res 2006;4(7):489–97)

This article has been cited by other articles:

				T. L. Tinder, D. B. Subramani, G. D. Basu, J. M. Bradley, J. Schettini, A. Million, T. Skaar, and P. Mukherjee MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma J. Immunol., September 1, 2008; 181(5): 3116 - 3125. [Abstract] [Full Text] [PDF]

				Q. Shen, J. J. Rahn, J. Zhang, N. Gunasekera, X. Sun, A. R.E. Shaw, M. J. Hendzel, P. Hoffman, A. Bernier, and J. C. Hugh MUC1 Initiates Src-CrkL-Rac1/Cdc42-Mediated Actin Cytoskeletal Protrusive Motility after Ligating Intercellular Adhesion Molecule-1 Mol. Cancer Res., April 1, 2008; 6(4): 555 - 567. [Abstract] [Full Text] [PDF]

				M.-K. Shyu, M.-C. Lin, J.-C. Shih, C.-N. Lee, J. Huang, C.-H. Liao, I-F. Huang, H.-Y. Chen, M.-C. Huang, and F.-J. Hsieh Mucin 15 is expressed in human placenta and suppresses invasion of trophoblast-like cells in vitro Hum. Reprod., October 1, 2007; 22(10): 2723 - 2732. [Abstract] [Full Text] [PDF]

				P. K. Singh, Y. Wen, B. J. Swanson, K. Shanmugam, A. Kazlauskas, R. L. Cerny, S. J. Gendler, and M. A. Hollingsworth Platelet-Derived Growth Factor Receptor {beta}-Mediated Phosphorylation of MUC1 Enhances Invasiveness in Pancreatic Adenocarcinoma Cells Cancer Res., June 1, 2007; 67(11): 5201 - 5210. [Abstract] [Full Text] [PDF]